Submission of Matters to a Vote of Security



On June 9, 2020, Corvus Pharmaceuticals,Inc. (the Company) held its
2020 Annual Meeting of Stockholders (the Annual Meeting). Only stockholders of record at the close of business on
April 13, 2020, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, there
were 27,953,233 shares of the Companys common stock outstanding and entitled to vote at the Annual Meeting. At the Annual
Meeting, 24,166,491 shares of the Companys common stock were voted in person or by proxy for the two proposals set forth
below, each of which is described in the Companys Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities
and Exchange Commission on April 15, 2020.



The tabulation of the stockholder votes on each proposal brought before the Annual Meeting
is as follows:



Proposal No.1 Election of Directors



The Companys stockholders elected the ClassI director nominees below to
the Companys Board of Directors to hold office until the 2023 Annual Meeting of Stockholders or until their respective successors
are elected and qualified or appointed, or the earlier of their death, resignation or removal.





ClassIIIDirectorNominees



VotesFor



VotesWithheld



BrokerNon

-

Votes



Richard A. Miller, M.D.



20,522,672



73,472



3,570,347



Linda S. Grais, M.D. J.D.



20,503,321



92,823



3,570,347




Proposal No.2 Ratification
of Selection of Independent Registered Accounting Firm



The Companys stockholders ratified the selection of PricewaterhouseCoopers LLC
as the independent registered public accounting firm of the Company for its fiscal year ending December31, 2020.





VotesFor



VotesAgainst



Abstain




24,158,965



3,559



3,967














SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.









CORVUS PHARMACEUTICALS, INC.







Date: June 10, 2020



By:


/s/ Leiv Lea






Leiv Lea






Chief Financial Officer





















makes a similar move, sign up!

Other recent filings from the company include the following:

On September - Sept. 17, 2020
Corvus Pharmaceuticals, Inc. director was just granted 30,000 options - Sept. 15, 2020
Corvus Pharmaceuticals, Inc. director just declared 0 ownership of the company. - Sept. 15, 2020
Departure of Directors or Certain - Sept. 11, 2020
On September - Sept. 10, 2020

Auto Refresh

Feedback